Novel therapeutic interventions for pseudoachondroplasia

Area of Science:

• Skeletal Dysplasias
• Molecular Biology
• Biochemistry

Background:

• Pseudoachondroplasia (PSACH) is a severe skeletal dysplasia characterized by short limbs, joint pain, and early osteoarthritis.
• Mutations in cartilage oligomeric matrix protein (COMP) disrupt its folding, calcium binding, and extracellular matrix export, leading to intracellular retention.

Purpose of the Study:

• To review the pathological mechanisms of mutant COMP (MT-COMP) in PSACH.
• To evaluate anti-inflammatory and antioxidant therapeutic strategies for reducing endoplasmic reticulum (ER) stress in MT-COMP chondrocytes.

Main Methods:

• Utilized mutant-COMP (MT-COMP) mouse models to study PSACH pathogenesis.
• Administered aspirin and resveratrol to MT-COMP mice to assess their impact on ER stress, chondrocyte death, and long-bone growth.

Main Results:

• MT-COMP accumulation in growth plate chondrocytes induces significant ER stress, inflammation, and oxidative stress, leading to chondrocyte death and impaired long-bone growth.
• Aspirin and resveratrol treatment decreased intracellular MT-COMP accumulation, reduced chondrocyte death, and lowered inflammatory marker expression.
• Therapeutic intervention resulted in improved long-bone growth in MT-COMP mice.

Conclusions:

• Intracellular COMP retention is a key driver of chondrocyte pathology in PSACH.
• Anti-inflammatory and antioxidant therapies targeting ER stress show promise in ameliorating PSACH phenotypes and improving skeletal growth.